AzTrials
AzTrials

Adjuvants, AnesthesiaPhase 2/3NCT03021772

Neostigmine Versus Dexamethasone as Adjuvants to Lidocaine During Intravenous Local Anesthesia

A Phase 2/3 study testing Neostigmine and Dexamethasone in people with Adjuvants, Anesthesia, run by Assiut University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Intravenous regional anesthesia (IVRA) is described firstly in 1908 by August Bier. It is simple, safe, reliable, less cost, efficient method in forearm surgery. The advantage of this method has fast return of motor and sensory function which enables patients for earlier discharge. Read more about this study

Who is it for?
Ages 20 to 60 years
Conditions the study is for
Adjuvants, Anesthesia
What is being tested?
Neostigmine and Dexamethasone
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteEgypt
Study dates
Jan 2017to 30 Sep 2018
Phase
Phase 2/3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Age from 20 - 60 years.
  • ASA grade I - II.
  • Surgical time does not exceed 90 minutes.

Who cannot join

  • Patient refusal.
  • Any contraindication of regional anesthesia block (e.g. Coagulopathy, infection at the needle insertion site or vascular insufficiency).
  • A personal history of seizures, peripheral neurologic diseases, cardiac arrhythmias, sickle cell anemia, liver dis¬ease, renal dysfunction and cardiac conduction abnormalities.
  • Patients with allergy to amide local anesthetics or medication included in the study.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Assiut university hospital

    Asyut, 71515

Other trials in Egypt

About this study

Official title: Efficacy of Neostigmine Versus Dexamethasone as Adjuvants to Lidocaine During Intravenous Local Anesthesia for Forearm Orthopedic Surgeries

Intravenous regional anesthesia (IVRA) is described firstly in 1908 by August Bier. It is simple, safe, reliable, less cost, efficient method in forearm surgery. The advantage of this method has fast return of motor and sensory function which enables patients for earlier discharge. However, this method has disadvantages such as tourniquet pain, insufficient muscle relaxation and postoperative analgesia.

Lidocaine inhibits action potential propagation within neuronal tissue by binding to receptors in Na+ channels located on the nerve cell membrane. Lidocaine IVRA is safe and effective and is associated with a rapid onset (4.5 minutes) of anesthesia after injection and termination of analgesia (5.8 ± 0.5 minutes) once the tourniquet is deflated.

Read more

Neostigmine is a typical cholinesterase inhibitor. It increases the level of acetylcholine (Ach) and indirectly stimulates both nicotinic and muscarinic receptors. In anesthesia, neostigmine is a drug that has been used for reversal of residual neuromuscular block. Administration of neostigmine by intrathecal and epidural routes has been found to cause analgesia by inhibition of the breakdown of Ach in the spinal cord.

Dexamethasone is commonly used in anesthesia to prevent postoperative nausea and vomiting (PONV). Two recent meta-analyses have documented that dexamethasone also reduced postoperative pain and opioid requirement. Intravenous dexamethasone has also been shown to improve postoperative pain control in patients receiving spinal or epidural morphine.

Hong et al reported that intravenous dexamethasone in combination with a caudal block with ropivacaine prolonged the duration of postoperative analgesia without adverse effects in children undergoing orchidopexy. So the investigators expect that addition of dexamethasone or neostigmine will affect duration and postoperative analgesia in bier block.

Read the detailed description

This study will be a prospective clinical randomized controlled double-blind study using a computer-generated randomization. Neither the doctor "investigator" nor the participant "patient" will be aware of the group allocation or the drug used. The study drugs will be prepared by one of the supervisor anesthesiologists (not included in the procedure, observation or data collection).

The study will be carried out in Assiut University Hospital after approval from our local ethical committee.

Patients

The patients will be classified in two groups:

According to sample size calculator. Group D: will include 30 patients and will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for bier block.

Group N: will include 30 patients and will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for bier block.

Methods

Before the procedure, the patient should be:

  • Starved for 6-8 hours.
  • Monitored closely (standard monitoring applied: HR, NIBP, SaO2 and RR)
  • Adequately informed about the procedure and have consented to it.

The equipments required for IVRA include:

  • Pneumatic tourniquet (checked for leaks before the procedure) and a pressure gauge.
  • Esmarch bandage or Rhys-Davis exsanguination.
  • Local anesthetic solution and the adjuvants.
  • Resuscitation equipments and drugs.

Technique:

IVRA of the arm: a 22 G cannula is placed intravenously as distal as possible in the arm to be anesthetized. Venous access is established in the opposite arm to allow administration of fluids or other drugs if necessary. The double tourniquet (two tourniquets each 6 cm wide) or a single one (14 cm wide) is applied on the operated arm with generous layers of padding, ensuring that no wrinkles are formed and the tourniquet edges do not touch the skin.

The arm is exsanguinated either by using the Esmarch bandage or a Rhys-Davis exsanguinator. If this is impossible, exsanguination can be achieved by elevating the arm for 2-3 minutes while compressing the axillary artery. The distal tourniquet is inflated to at least 100 mm Hg higher than the patient's systolic blood pressure (250 - 300 mmHg). The proximal tourniquet is inflated to the same pressure.

After ensuring inflation, the distal cuff is deflated. Before injecting local anesthetic, it must be confirmed that no radial pulse is palpable. The local anesthetic is then injected slowly. A standard volume for injection into the upper limb is 40 ml, which can be increased to 50 ml in a fit, large adult.

If the injection is too rapid, the venous pressure may exceed the tourniquet pressure and the local anesthetic solution may escape into the systemic circulation. Surgical anesthesia is usually achieved within 15 minutes. The distal tourniquet, which overlies part of the anesthetized arm, can then be inflated and the proximal one deflated to relieve tourniquet pain. The cuff should not be deflated until 20 minutes after local anesthetic injection because systemic toxic doses of local anesthetic may occur.

Cuff deflation should be performed in cycles with deflation/inflation times of less than 10 seconds until the patient no longer exhibits signs of systemic toxicity (e.g. tingling of the lips, tinnitus or drowsiness). Therefore, the patient should be monitored closely for 30 minutes following tourniquet release. So, the investigators expect that addition of dexamethasone or neostigmine will affect duration and postoperative analgesia.

Data collection:

  1. Patient's data: include patient's gender, age, weight, height, BMI and ASA classification.
  2. Preoperative data:
  3. Basic Monitoring: heart rate (HR), non-invasive blood pressure (NIBP), arterial oxygen saturation (SaO2), respiratory rate (RR) will be recorded.
  4. Preoperative investigations: prothrombin time, prothrombin concentration and INR to avoid any risk of internal bleeding.
  5. Basal assessment of motor power and sensation of the limb:

<!-- -->

  1. Motor power: Motor block was evaluated by thumb abduction (radial nerve), thumb adduction (ulnar nerve), thumb opposition (median nerve), and flexion at the elbow (musculocutaneous nerve) on a 3-point scale for motor function (0: normal motor function, 1: reduced motor strength but able to move fingers, 2: complete motor block).
  2. Sensation: Sensory block (4 nerves) was assessed by ice packs using a 3-point scale: 0: normal sensation, 1: loss of sensation of cold (analgesia), 2: loss of sensation of touch (anesthesia). d- The standard value of visual analogue scale will be set as the score during passive exercise before the surgery.
  3. Introperative data:
  4. Basic Monitoring: heart rate (HR), non-invasive blood pressure (NIBP), arterial oxygen saturation (SaO2), respiratory rate (RR) will be recorded every 10 minutes till the end of surgery.
  5. Sensory and motor block: Sensory and motor blocks will be evaluated every 5 minutes until 20 minutes after injection. Onset time will be defined as the time interval between the end of total local anesthetic administration and complete sensory block. Complete sensory block will be defined by anesthetic block (score 2) on all nerve territories. Complete motor block will be defined as absence of voluntary movement on hand and forearm (score 0). c- Duration of surgery.
  6. Postoperative data:
  7. Duration of sensory and motor block: Duration of sensory block will be defined as the time interval between the end of local anesthetic administration and the complete resolution of anesthesia on all nerves. Duration of motor block will be defined as the time interval between the end of local anesthetic administration and the recovery of complete motor function of the hand and forearm.
  8. Duration of analgesia: interval between onsets of the block to the time of the first analgesic requirement.
  9. Analgesia assessment: Postoperatively, a Post-Anesthesia Care Unit (PACU) nurse will assess the quality of analgesia. The pain score will be recorded using the Visual Analouge Scale (VAS) 2, 4, 6, 12 and 24 hours after surgery. Significant pain is defined as one that has a score of ≥ 4 and as a consequence required a supplementary dose of analgesia. Intravenous Paracetamol 15 mg/kg, will be administered and recorded. d- Documentation of any complications: Includes local anesthetic toxicity \& drug additives complications. Local anesthetic toxicity:
  • Initial symptoms are subjective and include perioral tingling or numbness, lightheadedness, tinnitus, metallic taste, slurred speech, auditory and visual disturbances.
  • Minor symptoms usually do not require treatment. If any of these occur observe patient closely and identify any potential reasons for systemic toxicity eg: check for cuff failure - re-inflate.
  • Significant neurotoxicity: Objective signs are usually excitatory: twitching, fasciculation and seizures:
  • Check for cuff failure - re-inflate immediately
  • Administer Midazolam 2.5-5.0 mg iv
  • Support the ABC's as indicated Most seizures are self-limiting but can be potentiated by hypoxia, acidosis and hypercarbia so these should be treated aggressively.
  • Significant cardiotoxicity: if occurs (eg: hypotension, bradycardia and arrhythmias): Give oxygen and adopt an ACLS approach Check for cuff failure - re-inflate immediately Bicarbonate may be indicated to address acidaemia. Drug additives complications: All patients will be monitored for any complications that may occur from any adjuvant drugs used in the study and will be treated promptly. Statistical analysis All data will be collected and analyzed using SPSS version 20 (SPSS, Inc., Chicago, Illinios, USA). Normally distributed data will be expressed as mean ± standard deviation, range, numbers and percentages. A probability (p) value of less than 0.05 will be considered statistically significant.
Being tested
Neostigmine, Dexamethasone
Keywords
Neostigmine, Dexamethasone, Intravenous Local Anesthesia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • NeostigmineDrug

    Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for Bier block.

  • DexamethasoneDrug

    Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for Bier block.

Study groups in NCT03021772
Study groupRoleWhat they receive
Group NActive comparator30 patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for Bier block.
Receives: Drug: Neostigmine
Group DActive comparator30 patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for Bier block.
Receives: Drug: Dexamethasone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pain assessed on VAS

    perfalgan will be given when visual analogue score ≥ 4

    Measured: 24 hours

Secondary outcomes (3)
  1. Sensory level

    duration of sensory block

    Measured: 2 hours

  2. Motor level

    duration of motor block

    Measured: 2 hours

  3. Number of patients with any complications

    Percentage of patients with any complications will be recorded

    Measured: 24 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Jan 2017 (estimated)
  2. Study startJan 2017
  3. Primary completion30 Sep 2018
  4. Study completion30 Sep 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2/3
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03021772
Sponsor's protocol ID
Bier Block
Status last verified
Jan 2019
First submitted
10 Jan 2017
Last updated
23 Jan 2019
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing Neostigmine and Dexamethasone in people with Adjuvants, Anesthesia, run by Assiut University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Jan 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pain assessed on VAS (time frame: 24 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jan 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in